Allspring Global Investments Holdings LLC Cuts Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Allspring Global Investments Holdings LLC lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 21.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 175,529 shares of the company’s stock after selling 48,135 shares during the period. Allspring Global Investments Holdings LLC owned about 0.31% of Protagonist Therapeutics worth $4,848,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of PTGX. Bank of New York Mellon Corp increased its stake in shares of Protagonist Therapeutics by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 139,769 shares of the company’s stock valued at $3,310,000 after purchasing an additional 1,275 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of Protagonist Therapeutics by 58.5% in the 1st quarter. MetLife Investment Management LLC now owns 23,914 shares of the company’s stock valued at $566,000 after purchasing an additional 8,826 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Protagonist Therapeutics by 5.6% in the 1st quarter. Rhumbline Advisers now owns 46,426 shares of the company’s stock valued at $1,099,000 after purchasing an additional 2,457 shares in the last quarter. Lord Abbett & CO. LLC increased its stake in Protagonist Therapeutics by 68.5% during the 1st quarter. Lord Abbett & CO. LLC now owns 275,787 shares of the company’s stock worth $6,531,000 after buying an additional 112,123 shares in the last quarter. Finally, First Trust Advisors LP purchased a new stake in Protagonist Therapeutics during the 1st quarter worth approximately $989,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on PTGX shares. JPMorgan Chase & Co. cut their price objective on Protagonist Therapeutics from $36.00 to $34.00 and set an “overweight” rating for the company in a research note on Monday, September 25th. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, October 10th. JMP Securities boosted their price objective on Protagonist Therapeutics from $35.00 to $37.00 and gave the stock a “market outperform” rating in a research note on Friday. StockNews.com lowered Protagonist Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Finally, Capital One Financial initiated coverage on Protagonist Therapeutics in a research note on Monday, October 30th. They set an “overweight” rating and a $32.00 price objective for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $36.40.

Protagonist Therapeutics Price Performance

PTGX stock opened at $16.65 on Friday. The business has a 50 day simple moving average of $16.86 and a 200-day simple moving average of $21.23. The firm has a market capitalization of $957.87 million, a PE ratio of -6.21 and a beta of 1.85. Protagonist Therapeutics, Inc. has a 1 year low of $7.24 and a 1 year high of $30.10.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.03). On average, equities research analysts expect that Protagonist Therapeutics, Inc. will post -2.64 EPS for the current year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease.